Delpazolid
An oxazolidinone antibiotic
Delpazolid | |
---|---|
![]() | |
INN | |
Drug class | |
Routes of administration | |
Pregnancy category | |
Bioavailability | |
Metabolism | |
Elimination half-life | |
Excretion | |
Legal status | |
CAS Number | |
PubChem | |
DrugBank | |
ChemSpider | |
KEGG |
Delpazolid is an investigational antibiotic belonging to the oxazolidinone class. It is being developed for the treatment of tuberculosis and other bacterial infections.
Mechanism of Action[edit | edit source]
Delpazolid works by inhibiting bacterial protein synthesis. It binds to the 50S subunit of the bacterial ribosome, thereby preventing the formation of the 70S initiation complex, which is essential for bacterial translation. This mechanism is similar to that of other oxazolidinones, such as linezolid.
Pharmacokinetics[edit | edit source]
Delpazolid is administered orally and has been shown to have good bioavailability. It is metabolized in the liver and excreted primarily through the kidneys. The pharmacokinetic profile of delpazolid supports its use in treating systemic infections, as it achieves therapeutic concentrations in the blood and tissues.
Clinical Development[edit | edit source]
Delpazolid is currently undergoing clinical trials to evaluate its efficacy and safety in treating multidrug-resistant tuberculosis (MDR-TB) and other serious bacterial infections. Early studies have shown promising results, with delpazolid demonstrating activity against a range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).
Potential Benefits[edit | edit source]
The development of delpazolid is particularly important in the context of increasing antibiotic resistance. As a new member of the oxazolidinone class, delpazolid offers a potential alternative for treating infections that are resistant to existing antibiotics. Its oral formulation also provides an advantage in terms of ease of administration compared to intravenous antibiotics.
Safety and Tolerability[edit | edit source]
In clinical trials, delpazolid has been generally well-tolerated. Common side effects include gastrointestinal disturbances, such as nausea and diarrhea. As with other oxazolidinones, there is a potential risk of myelosuppression, particularly with prolonged use. Monitoring of blood counts is recommended during treatment.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD